A non-hormonal drug called PP405, developed by Pelage Pharmaceuticals, is showing real promise for people who get no benefit from finasteride. In a Phase 2a trial, 31% of men with advanced baldness gained more than 20% hair density by week eight, compared to 0% in the placebo group. PP405 works through an entirely different biological mechanism than finasteride — it forces cells to produce excess lactate, which reactivates dormant hair follicle stem cells — meaning it can potentially regrow hair in areas where hormonal treatments have already failed. PP405 is not the only candidate in the pipeline. Clascoterone, pyrilutamide, and GT20029 are all advancing through clinical trials with mechanisms distinct from the 5-alpha-reductase inhibition that finasteride relies on.
If any of these reach approval, it would mark the first new class of hair loss drug the FDA has cleared since finasteride in 1997 — nearly three decades without a novel therapeutic approach. This matters beyond vanity. Hair loss is deeply tied to psychological well-being, and for people already managing cognitive decline or dementia, the compounding effect of visible physical changes can worsen depression, social withdrawal, and overall quality of life. An October 2025 study linked finasteride itself to depression and suicide risk, making the search for alternatives not just cosmetic but genuinely urgent from a brain health perspective. Below, we examine each of these new treatments, how they differ from one another, and what the realistic timelines look like.
Table of Contents
- Why Are New Hair Loss Drugs Needed When Finasteride Fails?
- How PP405 Reactivates Dormant Hair Follicles Without Hormones
- Clascoterone’s Topical Approach to Blocking DHT at the Follicle
- How Pyrilutamide and GT20029 Compare as Androgen Receptor Blockers
- The Depression and Suicide Risk That Changed the Conversation
- Why Non-Hormonal Hair Loss Treatments Matter for Brain Health
- What Realistic Timelines Look Like for These New Treatments
- Conclusion
- Frequently Asked Questions
Why Are New Hair Loss Drugs Needed When Finasteride Fails?
finasteride works by blocking the enzyme 5-alpha-reductase, which converts testosterone into dihydrotestosterone (DHT). DHT is the hormone responsible for shrinking hair follicles in androgenetic alopecia. The problem is that finasteride only reduces DHT levels by about 70%, and for a significant number of patients, that reduction is simply not enough. It is also completely ineffective for autoimmune-related hair loss, which follows a different biological pathway entirely. The side effect profile adds another layer of concern.
Beyond the well-documented sexual side effects, the October 2025 study published and reported by ScienceDaily found a meaningful association between finasteride use and increased risk of depression and suicidal ideation. For older adults — particularly those with early cognitive decline or a history of mood disorders — this risk profile is unacceptable. The FDA has also issued warnings about side effects from topical finasteride products, which were once considered a safer alternative to oral formulations. The result is a large population of people who either cannot tolerate finasteride, do not respond to it, or have conditions it was never designed to treat. That gap has driven a wave of drug development focused on non-hormonal mechanisms, topical androgen receptor blockers, and stem cell reactivation strategies that sidestep finasteride’s limitations entirely.
How PP405 Reactivates Dormant Hair Follicles Without Hormones
PP405 takes the most radically different approach of any drug in the current pipeline. Rather than targeting hormones or androgen receptors, it blocks pyruvate from entering the mitochondria. this forces cells to convert pyruvate into lactate instead, and the excess lactate acts as a signal that reactivates hair follicle stem cells that have gone dormant. It is a metabolic intervention, not an endocrine one. The Phase 2a trial results are encouraging but early. The 31% of men who gained more than 20% hair density did so by week eight — a relatively short timeframe for hair regrowth studies.
Pelage Pharmaceuticals plans to initiate Phase 3 studies in 2026, which will provide much larger datasets and longer follow-up periods. However, Phase 2a trials are small by design, and the jump to Phase 3 often reveals limitations that earlier trials did not capture. A drug can look transformative in 50 patients and underwhelming in 500. One genuine advantage worth noting: because PP405 is non-hormonal, it is potentially effective in both men and women. Finasteride is not approved for use in women and is actually contraindicated during pregnancy. If PP405’s Phase 3 data holds up, it could become the first hair loss drug that works across sexes through a single mechanism — a significant gap in current treatment options.
Clascoterone’s Topical Approach to Blocking DHT at the Follicle
Clascoterone 5% topical solution, developed by Cosmo Pharmaceuticals, takes a different strategy. It is a topical androgen receptor inhibitor, meaning it blocks DHT directly at the hair follicle without entering the systemic bloodstream in meaningful quantities. Think of it as putting the shield exactly where the damage happens, rather than reducing the weapon’s supply throughout the entire body the way finasteride does. The Phase 3 results from the SCALP 1 and SCALP 2 trials were striking: up to 539% relative improvement in target-area hair count compared to placebo. That number deserves context — relative improvement percentages can sound dramatic when the baseline is low.
If a placebo group gains 2 hairs per square centimeter and the treatment group gains about 13, that is a large relative difference but a modest absolute one. Still, the consistency across two large Phase 3 trials is genuinely noteworthy. If approved, clascoterone would be the first new therapeutic mechanism for androgenetic alopecia in over 30 years. Cosmo plans to complete the required 12-month safety follow-up by spring 2026, after which parallel FDA and EMA submissions are expected. The topical delivery is particularly relevant for older patients and those on multiple medications, since systemic drug interactions would be minimal — an important consideration for anyone managing dementia-related prescriptions alongside other health concerns.
How Pyrilutamide and GT20029 Compare as Androgen Receptor Blockers
Kintor Pharmaceutical is advancing two candidates simultaneously: pyrilutamide (KX-826) and GT20029. Both are topical androgen receptor blockers, but they differ in their chemical structures and delivery mechanisms. Pyrilutamide competitively binds to the androgen receptor, physically occupying the site so DHT cannot attach. This is mechanistically distinct from finasteride, which never touches the androgen receptor at all — it only reduces how much DHT is produced. Phase II trials of pyrilutamide showed that the topical application does not cause systemic buildup in the bloodstream, which means the sexual and psychological side effects associated with oral finasteride are unlikely to occur. The reported side effects were mild: redness, irritation, and dry or itchy skin at the application site.
Kintor expects to submit a new drug application to China’s NMPA in 2026, with potential commercialization in China by 2027. It is not yet on track for FDA approval, so patients in the United States and Europe should not expect access in the near term. GT20029’s Phase II results, published in December 2025, showed significant improvements in hair density and the drug is advancing toward Phase III trials. The tradeoff between these two Kintor drugs and Cosmo’s clascoterone is essentially geographic availability versus trial maturity. Clascoterone is further along in the Western regulatory pipeline, while Kintor’s drugs may reach Asian markets first. For patients evaluating options, the practical question is not just which drug works best but which drug will be available where they live and when.
The Depression and Suicide Risk That Changed the Conversation
The October 2025 study linking finasteride to depression and suicide risk was not the first warning signal, but it was the most impactful. Previous reports had been largely anecdotal or drawn from adverse event databases, which are useful for generating hypotheses but not for establishing causation. The 2025 study brought more rigorous methodology to the question, and its findings were concerning enough that the FDA issued additional warnings. For people with dementia or mild cognitive impairment, this finding has particular weight. Depression is already the most common psychiatric comorbidity in dementia, affecting up to 40% of patients depending on the study and the stage of disease.
Adding a medication that independently increases depression risk to someone already vulnerable is a clinical decision that many neurologists and geriatricians would resist. Caregivers and family members should be aware that if a loved one with cognitive decline is taking finasteride and experiencing mood changes, the hair loss medication may be contributing. This does not mean every person on finasteride will experience psychiatric side effects. Many people tolerate the drug without issue for years. But the risk-benefit calculation has shifted, particularly for older adults, and the availability of mechanistically different alternatives — even if they are still in trials — changes the clinical landscape. Patients who discontinue finasteride due to side effects now have reasonable hope that non-hormonal or topical-only options will reach the market within the next few years.
Why Non-Hormonal Hair Loss Treatments Matter for Brain Health
The connection between hair loss treatment and brain health is more direct than most people assume. DHT, the hormone that finasteride suppresses, is not only active in hair follicles. It plays roles in neurosteroid production, mood regulation, and possibly neuroprotection.
Suppressing it systemically — as oral finasteride does — can have downstream effects on brain chemistry that researchers are still working to fully characterize. Non-hormonal drugs like PP405 bypass this concern entirely. By targeting metabolic pathways in the follicle rather than suppressing a hormone that operates throughout the body, they avoid the neurological uncertainties that come with systemic DHT reduction. For patients in the early stages of cognitive decline, or for caregivers managing complex medication regimens, a hair loss treatment that carries zero hormonal risk to the brain is not a minor advantage — it is potentially the deciding factor in whether the treatment is appropriate at all.
What Realistic Timelines Look Like for These New Treatments
The most common mistake in following drug development is treating Phase 2 results as a guarantee of approval. PP405’s Phase 3 trials are set to begin in 2026, and Phase 3 studies for hair loss typically require 12 to 24 months of treatment data plus additional time for analysis and regulatory review. A realistic earliest approval date for PP405, if everything goes well, would be 2028 or 2029.
Clascoterone is further along — its Phase 3 data already exists, and FDA submission is expected after the safety follow-up concludes in spring 2026, making a potential approval in late 2026 or 2027 more plausible. Patients currently dissatisfied with finasteride should not abandon proven treatments while waiting for these new options, but they should have honest conversations with their dermatologists about the evolving landscape. For those managing both hair loss and cognitive health concerns, the key development to watch is clascoterone’s FDA submission, as it represents the nearest-term option with the most mature safety and efficacy data.
Conclusion
The nearly 30-year gap since finasteride’s approval is finally closing. PP405’s non-hormonal stem cell reactivation, clascoterone’s topical DHT blocking, and Kintor’s androgen receptor inhibitors each represent genuinely novel mechanisms that could help the substantial number of patients for whom finasteride either does not work or carries unacceptable risks. The October 2025 findings linking finasteride to depression and suicide risk have added urgency to an already active research pipeline.
For readers of this site, the intersection with brain health is the critical angle. Any medication that affects hormones systemically can influence mood, cognition, and neurological function — and the new generation of hair loss treatments is specifically designed to avoid that. Whether you are managing your own hair loss alongside cognitive health concerns or helping a loved one navigate these decisions, the most important step is staying informed about which treatments reach approval and discussing them with a physician who understands both dermatological and neurological priorities.
Frequently Asked Questions
Can I use PP405 right now if finasteride is not working for me?
No. PP405 is still in clinical trials. Phase 3 studies are expected to begin in 2026, and the drug would not be available to the general public until after successful completion of those trials and FDA approval, likely no earlier than 2028.
Is clascoterone the same as the acne medication Winlevi?
Clascoterone is the same active ingredient used in Winlevi (clascoterone 1% cream for acne), but the hair loss formulation is a 5% topical solution being studied specifically for androgenetic alopecia. The concentration, formulation, and target condition are different.
Are these new drugs safe for people with dementia or on dementia medications?
The non-hormonal and topical-only mechanisms suggest a lower risk of systemic drug interactions, but none of these treatments have been specifically studied in dementia populations. Any new medication should be discussed with the prescribing neurologist or geriatrician before starting.
Should I stop taking finasteride because of the depression study?
Do not stop any medication without consulting your doctor. The study identified a statistical association, not a certainty that every user will be affected. Your physician can help weigh your individual risk factors, especially if you have a history of mood disorders or cognitive decline.
Will these new treatments work for women?
PP405’s non-hormonal mechanism makes it a candidate for use in both men and women. Clascoterone and pyrilutamide are being studied primarily in male pattern hair loss, though their topical delivery could make them viable for women in the future. Currently, no new drug in this pipeline has completed trials specifically in female patients.
